by | Jun 24, 2021 | Uncategorized
Source: Healio News The last few years have yielded “incredible numbers of new drugs approved and under development” in multiple myeloma, Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.This...
by | Jun 24, 2021 | Uncategorized
Source: Healio News Once weekly oral selinexor combined with pomalidomide and dexamethasone was well-tolerated in patients with heavily pretreated multiple myeloma, according to data from the multi-arm phase 1b/2 STOMP study presented at the virtual ASCO Annual...
by | Jun 24, 2021 | Uncategorized
Source: ASCO Daily News Dr. Mitul Gandhi, medical oncologist-hematologist at Virginia Cancer Specialists of the US Oncology Network, highlights therapeutic advances in multiple myeloma featured at the 2021 ASCO Annual Meeting. Transcript: ASCO Daily News: Welcome...
by | Jun 24, 2021 | Uncategorized
Source: Cure Today articles Recent findings merit further study of the immunosuppressive drug as therapy in patients with multiple myeloma. Read More
by MM360 Staff | Jun 23, 2021 | Uncategorized
Source: Cure Today articles Results from a recent study strongly support a treatment regimen of Darzalex with Revlimid and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma. Read More
by MM360 Staff | Jun 23, 2021 | Uncategorized
Source: ASCO Daily News Dr. Mitul Gandhi, a medical oncologist specializing in hematologic malignancies at Virginia Cancer Specialists, which is part of the US Oncology Network, highlights key abstracts from the #ASCO20 Virtual Scientific Program that aim to improve...
